ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells

被引:23
|
作者
Iwai, M
Hara, A
Andoh, T
Ishida, R
机构
[1] AICHI CANC CTR,RES INST,BIOCHEM LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN
[2] GIFU PHARMACEUT UNIV,DEPT BIOCHEM,MITAHORA,GIFU 502,JAPAN
[3] SOKA UNIV,FAC ENGN,HACHIOJI,TOKYO 192,JAPAN
关键词
checkpoint in M phase; topoisomerase II inhibitor; ICRF-193;
D O I
10.1016/S0014-5793(97)00282-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have shown previously that ICRF-193, a catalytic inhibitor of DNA topoisomerase II (topo II), delays cell cycle progression in HeLa S3 cells, We report here that the delay of the transition in M phase is observed when HeLa S3 cells were treated with ICRF-193 during metaphase, but not thereafter, ICRF-193 also delayed the degradation of cyclin B in the transition from M to G1 phase, while in Chinese hamster ovary (CHO) cells the drug did not delay the progression in M phase, Since HeLa S3 and CHO cells are 'stringent' and 'relaxed' in mitotic control, respectively, it is suggested that under topo II inhibition, the M phase checkpoint operates through an inability for chromosome segregation. (C) 1997 Federation of European Biochemical Societies.
引用
收藏
页码:267 / 270
页数:4
相关论文
共 50 条
  • [1] ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells
    Hossain, MS
    Akimitsu, N
    Takaki, T
    Hirai, H
    Sekimizu, K
    GENES TO CELLS, 2002, 7 (03) : 285 - 294
  • [2] Preparation of extended metaphase chromosomes from human cultured cells using a topoisomerase II inhibitor, ICRF-193
    Kohda, A
    Taguchi, H
    Okumura, K
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2001, 65 (05) : 1248 - 1251
  • [3] Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange
    Hamatake, M
    Andoh, T
    Ishida, R
    ANTI-CANCER DRUGS, 1997, 8 (06) : 637 - 642
  • [4] The SUMO pathway is required for selective degradation of DNA topoisomerase IIβ induced by a catalytic inhibitor ICRF-193
    Isik, S
    Sano, K
    Tsutsui, K
    Seki, M
    Enomoto, T
    Saitoh, H
    Tsutsui, K
    FEBS LETTERS, 2003, 546 (2-3): : 374 - 378
  • [5] Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193
    Robinson, Helen M. R.
    Bratlie-Thoresen, Sigrid
    Brown, Robert
    Gillespie, David A. F.
    CELL CYCLE, 2007, 6 (10) : 1265 - 1267
  • [6] INHIBITION OF DNA TOPOISOMERASE-II BY ICRF-193 INDUCES POLYPLOIDIZATION BY UNCOUPLING CHROMOSOME DYNAMICS FROM OTHER CELL-CYCLE EVENTS
    ISHIDA, R
    SATO, M
    NARITA, T
    UTSUMI, KR
    NISHIMOTO, T
    MORITA, T
    NAGATA, H
    ANDOH, T
    JOURNAL OF CELL BIOLOGY, 1994, 126 (06): : 1341 - 1351
  • [7] Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
    Nakazawa, Norihiko
    Arakawa, Orie
    Ebe, Masahiro
    Yanagida, Mitsuhiro
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (10) : 3772 - 3782
  • [8] Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb/3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II
    Nishida, K
    Seto, M
    Ishida, R
    JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (02): : 193 - 202
  • [9] Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and m phases of the cell cycle
    Muñoz, P
    Zdzienicka, MZ
    Blanchard, JM
    Piette, J
    MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (10) : 5797 - 5808
  • [10] Expression of topoisomerase IIα in the G0/G1 cell cycle phase of fresh leukemic cells
    Uggla, B
    Möllgård, L
    Ståhl, E
    Mossberg, LL
    Karlsson, MG
    Paul, C
    Tidefelt, U
    LEUKEMIA RESEARCH, 2001, 25 (11) : 961 - 966